Erratum to ‘Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database’ [European Journal of Cancer, Volume 125 (January 2020) Pages 153–163] (European Journal of Cancer (2020) 125 (153–163), (S0959804919308020), (10.1016/j.ejca.2019.10.030))

Autor: Delanoy, N. Hardy-Bessard, A.-C. Efstathiou, E. Moulec, S.L. Basso, U. Birtle, A. Thomson, A. Krainer, M. Guillot, A. Giorgi, U.D. Hasbini, A. Daugaard, G. Bahl, A. Chowdhury, S. Caffo, O. Beuzeboc, P. Spaeth, D. Eymard, J.-C. Fléchon, A. Alexandre, J. Helissey, C. Butt, M. Priou, F. Lechevallier, E. Deville, J.-L. Gross-Goupil, M. Morales, R. Thiery-Vuillemin, A. Gavrikova, T. Barthélémy, P. Sella, A. Fizazi, K. Ferrero, J.-M. Laguerre, B. Thibault, C. Hans, S. Oudard, S.
Jazyk: angličtina
Rok vydání: 2020
Popis: The publisher regrets that the following corrections were missed during the publication of this article. Figure 2 legend is missing from the published article and should appear as follows: Figure 2: Overall survival from initiation of each life-extending therapy in accordance with the type of progression in 661 patients with mCRPC. (A) OS from first life-extending therapy (LET) initiation (all arms combined), (B) OS from second LET initiation (all arms combined), and (C) OS from third LET initiation (all arms combined). Referring to Table 3, ‘Median OS (all arms combined) in months’, the 1st LET entry for the Clin-p column should appear as 30.7 [27.5; 32.9]. Referring to Figure 2A, median Clin-p should appear as 30.7 [27.5; 32.9]. The correct Figure is included here The publisher would like to apologise for any inconvenience caused. [Figure presented] © 2020 Elsevier Ltd
Databáze: OpenAIRE